Capital Analysts LLC
TARS icon

Capital Analysts LLC’s Tarsus Pharmaceuticals TARS Stock Holding History

Capital Analysts LLC’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$236 Buy
+3
New +$208 ﹤0.01% 1678

Other funds holding TARS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Capital Analysts LLC's TARS Position: Q3 2026 in Review

Capital Analysts LLC opened a new position in Tarsus Pharmaceuticals (TARS) in Q3 2026: 3 shares worth $236. The stake represents ﹤0.01% of the portfolio and ranks #1678 among its holdings.

176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • Capital Analysts LLC held 3 shares of Tarsus Pharmaceuticals worth $236 as of Q3 2026.
  • Tarsus Pharmaceuticals was a new Capital Analysts LLC position in Q3 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Capital Analysts LLC's portfolio in Q3 2026, its #1678 holding.
  • 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Capital Analysts LLC's 13F filing for Q3 2026, filed 13 Nov 2026.